Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2024

Genmab — April 2024

Planlagt Fastgjort Låst Flyttet Genmab
759 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #718

    Dejligt med endnu en god nyhed 🙂

    1 Reply Last reply
    0
    • V Offline
      V Offline
      Vitus
      wrote on sidst redigeret af
      #719

      Betyder det noget…..

      1 Reply Last reply
      0
      • W Offline
        W Offline
        w
        wrote on sidst redigeret af
        #720

        Alt er indregnet;)

        1 Reply Last reply
        0
        • V Offline
          V Offline
          Vitus
          wrote on sidst redigeret af
          #721

          Vor herre bev……

          1 Reply Last reply
          0
          • royalR Offline
            royalR Offline
            royal
            wrote on sidst redigeret af
            #722

            Lige før man håber på et dårligt Q1 på torsdag.

            1 Reply Last reply
            0
            • W Offline
              W Offline
              w
              wrote on sidst redigeret af
              #723

              Komplet uforståeligt at den kan falde på en godkendelse, der iøvrigt kom før tid

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #724

                This full approval is the minimum requirement to continue with Tivdak and therefore an important step. It will depend on how much new owner Pfizer sees in the drug, but the EMA application and current conversations with regulators to continue also in head and neck cancer bode well for now.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #725

                  Tivdak seems to go a little bit under the radar, but 'According to GlobalData’s patient-based forecast, Tivdak is forecast to generate sales of $1.4bn in the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada) by 2030'

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #726

                    Link Preview Image
                    Highlights from ESMO 2023: Antibody-drug conjugates and bispecific T-cell engagers

                    At ESMO 2023, much of the focus was on new data for antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs)

                    favicon

                    Clinical Trials Arena (www.clinicaltrialsarena.com)

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #727

                      i am sure we will still all be here in 2030 to see if that comes true, whilst complaining about the share price 😉

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        Bullish
                        wrote on sidst redigeret af
                        #728

                        OB og Genmab har noget til fælles for tiden..

                        1 Reply Last reply
                        0
                        • R Offline
                          R Offline
                          Riis7
                          wrote on sidst redigeret af
                          #729

                          Og fcm:-)

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            GeorgeBest
                            wrote on sidst redigeret af
                            #730

                            Thanks E L 09:48. Can you also see what’s the forecast for epcoritamab is by 2030?

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #731

                              'GlobalData’s consensus forecast forecasts that Epkinly will achieve blockbuster status by 2027, with global sales expected to exceed $1.9bn by 2029.' from may last year https://www.clinicaltrialsarena.com/analyst-comment/abbvie-genmab-epkinly-dlbcl/?cf-view

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #732

                                Due to Epkinly's tremendous efficacy, analysts at SVB Securities think that the drug could reach peak annual sales of $3 billion in the U.S. https://www.nasdaq.com/articles/could-this-new-drug-be-a-blockbuster-for-these-2-pharma-collaborators

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #733

                                  Sydbank epcoritamab
                                  He estimates the new drug’s annual peak sales potential at USD 3.5bn.https://medwatch.com/News/Pharma___Biotech/article15855008.ece

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #734

                                    Drug: Epcoritamab
                                    Companies: AbbVie and Genmab
                                    Used for: Lymphoma
                                    Est. 2028 sales: $1.7 billion https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2023

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #735

                                      Jefferies analysts previously predicted Epkinly could reach about $2.75 billion in peak sales.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #736

                                        Take your pick 😉

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #737

                                          the strength of the competition will greatly affect epco sales, it will be a battle

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper